Corneal transplantation remains a challenge within developing countries due to a lack of donor tissue and underdeveloped infrastructure. May Griffith, PhD, University of Montreal & Hopital Maisonneuve-Rosemont, Montreal, Canada, discusses the development of LiQD Cornea, a alternative to corneal transplantation in patients. Whereas other similar therapies require preparation of the pregel in a lab, LiQD Cornea gels within the cornea itself. The ease of administration will enable easier access to corneal treatments within the developing world, and mouse models have indicated preliminary efficacy. This interview took place at the 6th World Congress of the Tissue Engineering and Regenerative Medicine International Society (TERMIS 2021).
Prof. Griffith is a named inventor on PCT patents WO2007/028258 A2 Interpenetrating networks, and related methods and compositions, assigned to the Ottawa Hospital Research Institute and University of Ottawa; PCT/IB2017/056342 Collagen and CLP-based hydrogels, corneal implants, filler glue and uses thereof, which was assigned to the Hyderabad Eye Research Foundation, and then subsequently assigned to North Grove Investments, Inc. wherein PCT national phase applications have been filed in the USA, EU, India, China, and Canada. She is also a named inventors on a US provisional patent application no. 62916765, subsequent to a disclosure to Maisonneuve-Rosemont Hospital and Université de Montréal.